Objective To study the impact of independent R&D and collaborative innovation on economic performance in the pharmaceutical industry.Methods A panel regression model was established by selecting the panel data of ...Objective To study the impact of independent R&D and collaborative innovation on economic performance in the pharmaceutical industry.Methods A panel regression model was established by selecting the panel data of China’s pharmaceutical industry from 2009 to 2019.Results and Conclusion Independent R&D and collaborative innovation of the pharmaceutical industry in eastern,central and western regions of China had a positive effect on economic performance.Besides,the promotion effect of independent R&D was greater than that of collaborative innovation.The positive driving effect of economic performance is the largest among the three regions,followed by the central and western regions.The collaborative innovation has the greatest positive effect on economic performance in the central region,followed by the eastern and western regions.展开更多
Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low-and middle-income countries(LMICs).However,a gulf between paying markets and the endemicity of such ...Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low-and middle-income countries(LMICs).However,a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs.While the pharmaceutical industry views emerging economies as potential new markets,most of the world’s poorest bottom billion now reside in middle-income countries-a fact that has complicated tiered access arrangements.However,product development partnerships-particularly those involving academic institutions and small firms-find commercial opportunities in pursuing even neglected diseases;and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation.Such innovation will be shaped by 1)access to building blocks of knowledge;2)strategic use of intellectual property and innovative financing to meet public health goals;3)collaborative norms of open innovation;and 4)alternative business models,some with a double bottom line.Facing such resource constraints,LMICs are poised to develop a new,more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.展开更多
基金Research on the Innovation and Development Strategy of the Pharmaceutical Industry in Liaoning Province(No.2020lslktyb-095).
文摘Objective To study the impact of independent R&D and collaborative innovation on economic performance in the pharmaceutical industry.Methods A panel regression model was established by selecting the panel data of China’s pharmaceutical industry from 2009 to 2019.Results and Conclusion Independent R&D and collaborative innovation of the pharmaceutical industry in eastern,central and western regions of China had a positive effect on economic performance.Besides,the promotion effect of independent R&D was greater than that of collaborative innovation.The positive driving effect of economic performance is the largest among the three regions,followed by the central and western regions.The collaborative innovation has the greatest positive effect on economic performance in the central region,followed by the eastern and western regions.
文摘Enabling innovation and access to health technologies remains a key strategy in combating infectious diseases in low-and middle-income countries(LMICs).However,a gulf between paying markets and the endemicity of such diseases has contributed to the dearth of R&D in meeting these public health needs.While the pharmaceutical industry views emerging economies as potential new markets,most of the world’s poorest bottom billion now reside in middle-income countries-a fact that has complicated tiered access arrangements.However,product development partnerships-particularly those involving academic institutions and small firms-find commercial opportunities in pursuing even neglected diseases;and a growing pharmaceutical sector in BRICS countries offers hope for an indigenous base of innovation.Such innovation will be shaped by 1)access to building blocks of knowledge;2)strategic use of intellectual property and innovative financing to meet public health goals;3)collaborative norms of open innovation;and 4)alternative business models,some with a double bottom line.Facing such resource constraints,LMICs are poised to develop a new,more resource-effective model of innovation that holds exciting promise in meeting the needs of global health.
